Hicks, Charles B <br/><br/>
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.  [electronic resource] 

 -  Lancet (London, England)  Aug 2006 
 - 466-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(06)69154-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Enfuvirtide<br/>Female<br/>HIV Envelope Protein gp41--therapeutic use<br/>HIV Fusion Inhibitors--therapeutic use<br/>HIV Infections--drug therapy<br/>HIV Protease Inhibitors--administration & dosage<br/>HIV-1--genetics<br/>Humans<br/>Logistic Models<br/>Male<br/>Multicenter Studies as Topic<br/>Peptide Fragments--therapeutic use<br/>Pyridines--administration & dosage<br/>Pyrones--administration & dosage<br/>Randomized Controlled Trials as Topic<br/>Ritonavir--administration & dosage<br/>Sulfonamides<br/>Time Factors<br/>Treatment Failure<br/>Viral Load